<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: In the past 8 years, 120 cases of <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> were transplanted from the HLA identical donors </plain></SENT>
<SENT sid="1" pm="."><plain>METHOD: Using chemotherapy based conditioning regimen with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 200 mg/kg and <z:chebi fb="0" ids="28901">busulfan</z:chebi> 15-16 mg/kg, 80 cases of <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia major</z:e> and 35 cases of <z:hpo ids='HP_0001909'>leukemia</z:hpo> and five patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> had received bone marrow transplantation </plain></SENT>
<SENT sid="2" pm="."><plain>RESULT: The five-year-survival in thalassemic group was 72%, for leukemic group (<z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo>) was 58%, and also for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> 65% </plain></SENT>
<SENT sid="3" pm="."><plain>Transplantation related mortality was the cause of <z:hpo ids='HP_0011420'>death</z:hpo> in 29 cases </plain></SENT>
<SENT sid="4" pm="."><plain>The two major causes of <z:hpo ids='HP_0011420'>death</z:hpo> were <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> and poor medical condition of patients before marrow transplantation </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: At the present time, allogenic marrow transplantation is curative mode of treatment for many <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> </plain></SENT>
</text></document>